Omega Therapeutics, Inc.
Omega Therapeutics, Inc. is grouped at the issuer level across 1 linked ticker lifecycle, combining public listing, delisting, source, and shareholder outcome records from the archive.
Lifecycle Map
Issuer enters the archive
Jul 9, 2021Omega Therapeutics, Inc. is represented as an issuer-level entity with 1 linked public-market ticker lifecycle.
Delisting event
Mar 20, 2025Removed from listing - SEC Form 25 filed.
SourceOMGAQ stopped trading
Mar 20, 2025OMGAQ is linked to Omega Therapeutics, Inc. and ended with final status "bankrupt".
Source
Entity Graph
Omega Therapeutics, Inc.issuedOMGAQ
OMGAQlisted onNASDAQ
OMGAQresulted inunknown
Source-Backed Claims
- Omega Therapeutics, Inc. filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code on February 10, 2025, in the United States Bankruptcy Court for the District of Delaware.8-K
- The Chapter 11 case for Omega Therapeutics, Inc. is administered under the caption In re Omega Therapeutics, Inc., Case No. 25-10211.8-K
- On February 21, 2025, Omega Therapeutics, Inc. entered into a Stalking Horse Agreement to sell substantially all of its assets to Pioneering Medicines 08-B, Inc.8-K
- The Stalking Horse Agreement stipulates a purchase price of not less than $11,461,086.00 plus the assumption of certain liabilities.8-K
- Nasdaq notified Omega Therapeutics, Inc. on February 18, 2025, that its common stock would be delisted due to the company's commencement of Chapter 11 proceedings.8-K
- Trading of Omega Therapeutics, Inc.'s common stock is scheduled to be suspended at the opening of business on February 25, 2025.8-K
Associated Tickers
Public-market security lifecycles tied to this issuer record.